Cobimetinib

Cobimetinib is a potent, orally available inhibitor of MEK1 (IC50 = 4.2 nM). It shows more than 100-fold selectivity for MEK when tested against a panel of more than 100 serine-threonine and tyrosine kinases. Cobimetinib induces differentiation and apoptosis in cancer cell lines and is more effective when combined with additional inhibitors, like PLX4032 (Cay-10618).Formal Name: [3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]phenyl][3-hydroxy-3-(2S)-2-piperidinyl-1-azetidinyl]-methanone. CAS Number: 934660-93-2. Synonyms: GDC-0973, RG-7420, XL518. Molecular Formula: C21H21F3IN3O2. Formula Weight: 531.3. Purity: >98%. Formulation: (Request formulation change), A crystalline solid. Solubility: DMF: 33 mg/ml, DMSO: 25 mg/ml, Ethanol: 11 mg/ml. lambdamax: 240, 276 nm. SMILES: FC1=C(NC2=CC=C(I)C=C2F)C(C(N3CC([C@@H]4CCCCN4)(O)C3)=O)=CC=C1F. InChi Code: InChI=1S/C21H21F3IN3O2/c22-14-6-5-13(19(18(14)24)27-16-7-4-12(25)9-15(16)23)20(29)28-10-21(30,11-28)17-3-1-2-8-26-17/h4-7,9,17,26-27,30H,1-3,8,10-11H2/t17-/m0/s1. InChi Key: BSMCAPRUBJMWDF-KRWDZBQOSA-N.